NKGen Biotech, Inc. Common Stock (NKGN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NKGen Biotech, Inc. Common Stock (NKGN) with AI Score 53/100 (Hold). NKGen Biotech, Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026NKGen Biotech, Inc. Common Stock (NKGN) Healthcare & Pipeline Overview
NKGen Biotech, Inc. is a clinical-stage biotechnology firm specializing in autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases. With lead candidates in Phase I/IIa trials and strategic partnerships in place, NKGen aims to address unmet needs in Alzheimer's, Parkinson's, and refractory solid tumors within the competitive biotechnology landscape.
Investment Thesis
NKGen Biotech presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on NK cell therapies for neurodegenerative and oncological diseases addresses significant unmet medical needs. Successful clinical trials for SNK01 and SNK02 could drive substantial value. The strategic partnership with HekaBio K.K. provides access to the Japanese market. However, the company's negative profit margin of -1145.1% and reliance on early-stage clinical trials pose significant risks. The company's market capitalization is $0.01B. Investors should carefully weigh the potential upside against the inherent uncertainties of biotechnology development and regulatory approval processes.
Based on FMP financials and quantitative analysis
Key Highlights
- NKGen Biotech is a clinical-stage biotechnology company focused on NK cell therapies.
- Lead product candidate SNK01 is in Phase I/IIa trials for Alzheimer's and Parkinson's disease.
- Strategic partnership with HekaBio K.K. to develop and commercialize NK cell therapies in Japan.
- Gross margin of 50.0% indicates potential profitability upon successful commercialization.
- Market capitalization of $0.01B reflects the early stage of the company and associated risks.
Competitors & Peers
Strengths
- Proprietary NK cell activation technology.
- Strategic partnerships with HekaBio K.K. and NKMAX Co., Ltd.
- Early-stage clinical data demonstrating potential efficacy.
- Focus on underserved markets with high unmet medical needs.
Weaknesses
- Early-stage clinical development with high risk of failure.
- Negative profit margin and limited financial resources.
- Reliance on strategic partnerships for revenue generation.
- OTC market listing indicates higher risk and lower liquidity.
Catalysts
- Upcoming: Phase I/IIa clinical trial results for SNK01 in Alzheimer's and Parkinson's disease (2027-2028).
- Upcoming: Advancement of SNK02 through clinical trials for refractory solid tumors (2028-2030).
- Ongoing: Expansion of the strategic partnership with HekaBio K.K. into additional indications and territories.
- Ongoing: Securing additional funding through strategic partnerships, grants, or public offerings.
Risks
- Potential: Clinical trial failures or delays for SNK01 and SNK02.
- Potential: Regulatory hurdles and delays in obtaining approvals from the FDA and other agencies.
- Ongoing: Competition from other cell therapy companies in the neurodegenerative and oncological disease markets.
- Ongoing: Limited financial resources and reliance on strategic partnerships for revenue generation.
- Potential: Risks associated with trading on the OTC Other market, including low liquidity and price volatility.
Growth Opportunities
- Growth opportunity 1: Successful completion of Phase I/IIa trials for SNK01 in Alzheimer's and Parkinson's disease could unlock a substantial market opportunity. The global Alzheimer's disease therapeutics market is projected to reach $13.7 billion by 2028. Positive clinical data would validate NKGen Biotech's NK cell therapy platform and attract further investment and partnerships. Timeline: 2027-2028.
- Growth opportunity 2: Advancing SNK02, the allogeneic NK cell therapy, through clinical trials for refractory solid tumors represents another significant growth driver. The solid tumor therapeutics market is estimated to reach $250 billion by 2030. Successful development and commercialization of SNK02 could provide a valuable treatment option for patients with limited alternatives. Timeline: 2028-2030.
- Growth opportunity 3: Expansion of the strategic partnership with HekaBio K.K. into additional indications and territories could accelerate NKGen Biotech's growth. The Japanese market for cell therapies is rapidly expanding, driven by favorable regulatory policies and increasing demand for innovative treatments. Timeline: Ongoing.
- Growth opportunity 4: Leveraging the license agreement with NKMAX Co., Ltd. to develop new NK cell-based therapies could broaden NKGen Biotech's product pipeline and technological capabilities. This collaboration could lead to the discovery of novel targets and therapeutic approaches. Timeline: 2027-2029.
- Growth opportunity 5: Securing additional funding through strategic partnerships, grants, or public offerings is crucial for NKGen Biotech to advance its clinical programs and expand its operations. Successful fundraising would provide the necessary resources to support research and development, manufacturing, and commercialization efforts. Timeline: Ongoing.
Opportunities
- Successful completion of clinical trials for SNK01 and SNK02.
- Expansion of strategic partnerships into new indications and territories.
- Development of new NK cell-based therapies through collaboration with NKMAX Co., Ltd.
- Securing additional funding through strategic partnerships, grants, or public offerings.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other cell therapy companies.
- Changes in the regulatory landscape or reimbursement policies.
Competitive Advantages
- Proprietary NK cell activation technology.
- Strategic partnerships with HekaBio K.K. and NKMAX Co., Ltd.
- Early-stage clinical data demonstrating potential efficacy.
- Focus on underserved markets with high unmet medical needs.
About NKGN
NKGen Biotech, Inc., founded in 2017 and headquartered in Santa Ana, California, is a clinical-stage biotechnology company dedicated to developing and commercializing innovative cell therapies. The company's primary focus is on harnessing the power of activated natural killer (NK) cells to treat neurodegenerative and oncological diseases. Their lead product candidate, SNK01, is an autologous NK cell therapy currently in Phase I/IIa clinical trials for the treatment of neurodegenerative conditions such as Alzheimer's and Parkinson's disease. SNK02, another key asset, consists of an allogeneic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. NKGen Biotech has established a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize its autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. This collaboration expands the company's reach and potential market. Additionally, NKGen Biotech has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program, further strengthening its technological foundation.
What They Do
- Develop autologous NK cell therapy (SNK01) for neurodegenerative diseases.
- Develop allogeneic NK cell therapy (SNK02) for refractory solid tumors.
- Conduct Phase I/IIa clinical trials for SNK01.
- Conduct Phase 1 clinical trials for SNK02.
- Partner with HekaBio K.K. for development and commercialization in Japan.
- License technology from NKMAX Co., Ltd. for NK cell program research.
- Focus on cell therapies for neurodegenerative and oncological diseases.
Business Model
- Develop and out-license NK cell therapy technologies.
- Generate revenue through strategic partnerships and collaborations.
- Potentially generate revenue through direct sales of approved therapies.
- Focus on research and development of novel cell therapies.
Industry Context
NKGen Biotech operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for cell therapies, particularly in neurodegenerative and oncological diseases, is experiencing substantial growth. Key trends include the increasing adoption of personalized medicine, advancements in gene editing technologies, and growing demand for novel cancer treatments. NKGen Biotech's focus on NK cell therapies positions it within a niche segment of the market, competing with companies developing CAR-T cell therapies and other immunotherapies.
Key Customers
- Patients with Alzheimer's disease.
- Patients with Parkinson's disease.
- Patients with refractory solid tumors.
- Healthcare providers and hospitals.
Financials
Chart & Info
NKGen Biotech, Inc. Common Stock (NKGN) stock price: Price data unavailable
Latest News
-
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
globenewswire.com · Mar 23, 2026
-
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
globenewswire.com · Mar 10, 2026
-
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
defenseworld.net · Feb 8, 2026
-
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
defenseworld.net · Feb 2, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NKGN.
Price Targets
Wall Street price target analysis for NKGN.
MoonshotScore
What does this score mean?
The MoonshotScore rates NKGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
Leadership: Paul Y. Song
Unknown
Information on Paul Y. Song's background is not available in the provided context. Without additional data, it is impossible to provide details on his career history, education, previous roles, or credentials.
Track Record: Information on Paul Y. Song's track record is not available in the provided context. Without additional data, it is impossible to provide details on his key achievements, strategic decisions, or company milestones under his leadership.
NKGN OTC Market Information
The OTC Other tier, where NKGN trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting requirements, which increases investment risk. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies may not meet minimum listing standards related to financial performance, corporate governance, or market capitalization. This tier is considered highly speculative due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with the OTC market.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings.
- Strategic partnerships with established companies like HekaBio K.K.
- Clinical trials underway for lead product candidates.
- Focus on a specific therapeutic area with unmet medical needs.
- License agreement with NKMAX Co., Ltd. for NK cell program research.
NKGN Healthcare Stock FAQ
What does NKGen Biotech, Inc. Common Stock do?
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cell therapies based on activated natural killer (NK) cells. The company's lead product candidates, SNK01 and SNK02, target neurodegenerative diseases like Alzheimer's and Parkinson's, and refractory solid tumors, respectively. NKGen Biotech leverages its proprietary NK cell activation technology and strategic partnerships to advance its clinical programs and address unmet medical needs in these therapeutic areas. The company aims to provide innovative treatment options for patients with limited alternatives.
What do analysts say about NKGN stock?
AI analysis is pending for NKGN. Currently there is no available analyst consensus, valuation metrics, or growth considerations for NKGN stock. The company's early-stage clinical development and OTC market listing contribute to the uncertainty surrounding its future performance. Investors should conduct thorough due diligence and consider the inherent risks associated with biotechnology investments before making any decisions.
What are the main risks for NKGN?
The main risks for NKGen Biotech include the potential for clinical trial failures or delays, regulatory hurdles in obtaining approvals from the FDA and other agencies, competition from other cell therapy companies, limited financial resources, and risks associated with trading on the OTC Other market. The company's success depends on the successful development and commercialization of its NK cell therapies, which is subject to significant scientific, regulatory, and financial uncertainties. The OTC listing adds additional risks related to liquidity, transparency, and potential price volatility.
How does NKGen Biotech, Inc. Common Stock navigate regulatory approval processes?
As a clinical-stage biotechnology company, NKGen Biotech's success hinges on navigating complex regulatory approval processes, primarily with the FDA in the United States and potentially other agencies like the EMA in Europe, depending on future expansion plans. The company must demonstrate the safety and efficacy of its NK cell therapies through rigorous clinical trials. This involves submitting detailed data packages, participating in regulatory meetings, and adhering to strict manufacturing standards. Any delays or setbacks in the regulatory process could significantly impact the company's timeline and financial prospects.
What revenue streams does NKGen Biotech, Inc. Common Stock have in healthcare?
Currently, NKGen Biotech does not have established revenue streams from commercialized products, as it is a clinical-stage company. Its primary revenue sources are likely to be derived from strategic partnerships, licensing agreements, and potentially grants or government funding. The partnership with HekaBio K.K. is a key potential revenue driver, as it involves the development and commercialization of NKGen Biotech's therapies in Japan. Upon successful completion of clinical trials and regulatory approvals, the company could generate revenue through direct sales of its approved therapies to healthcare providers and hospitals.
What are the key factors to evaluate for NKGN?
NKGen Biotech, Inc. Common Stock (NKGN) currently holds an AI score of 53/100, indicating moderate score. Key strength: Proprietary NK cell activation technology.. Primary risk to monitor: Potential: Clinical trial failures or delays for SNK01 and SNK02.. This is not financial advice.
How frequently does NKGN data refresh on this page?
NKGN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NKGN's recent stock price performance?
Recent price movement in NKGen Biotech, Inc. Common Stock (NKGN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary NK cell activation technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for NKGN and may provide additional insights.
- OTC market investments carry significant risks.